ENDRA Life Sciences (NDRA) Notes Payables (2016 - 2023)

ENDRA Life Sciences (NDRA) has reported Notes Payables for 6 consecutive years, with $28484.0 the latest figure, recorded in Q4 2023.

• On a quarterly basis, Notes Payables changed 0.0% year-over-year to $28484.0 in Q4 2023; TTM through Dec 2023 was $28484.0, a 0.0% change from a year earlier, with the FY2023 full-year figure at $28484.0, changed 0.0% from the prior year.
• Notes Payables was $28484.0 for Q4 2023 at ENDRA Life Sciences, roughly flat from $28484.0 in the prior quarter.
• Over five years, Notes Payables peaked at $590026.0 in Q3 2019 and troughed at $28484.0 in Q4 2022.
• A 4-year average of $148633.3 and a median of $28484.0 in 2022 frame the typical range for Notes Payables.
• The widest YoY moves for Notes Payables: up 0.0% in 2023, down 0.0% in 2023.
• Over 4 years, Notes Payables stood at $298069.0 in 2019, then plunged by 87.12% to $38402.0 in 2020, then slipped by 25.83% to $28484.0 in 2022, then changed by 0.0% to $28484.0 in 2023.
• The last three Notes Payables figures came in at $28484.0 (Q4 2023), $28484.0 (Q3 2023), and $28484.0 (Q2 2023), per Business Quant data.